In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease

por Price, Diana L., Khan, Asma, Angers, Rachel, Cardenas, Alvaro, Prato, Maria Key, Bani, Massimo, Bonhaus, Douglas W., Citron, Martin, Biere, Anja-Leona
Publicado 2023

Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease

por Smit, Johan Willem, Basile, Peter, Prato, Maria Key, Detalle, Laurent, Mathy, François‐Xavier, Schmidt, Astrid, Lalla, Marianna, Germani, Massimiliano, Domange, Coralie, Biere, Anja‐Leona, Bani, Massimo, Carson, Stan, Genius, Just
Publicado 2022